Generate Biomedicines (GENB) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Generate Biomedicines is the larger company by market cap ($1.84 billion vs $1.80 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GENB | URGN |
|---|---|---|
| Share price | $14.34 | $36.83 |
| Market cap | $1.84B | $1.80B |
| 1-day change | +2.50% | -0.41% |
| YTD return | — | +57.26% |
| 1-year return | — | +124.30% |
| 5-year return | — | +116.39% |
| Forward P/E | — | 13.18 |
| EPS (TTM) | $-2.50 | $-1.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $109.79M |
| Revenue growth (YoY) | — | +21.45% |
| Net income (latest FY) | — | $-153.49M |
| Gross margin | — | 88.66% |
| Operating margin | — | -113.73% |
| Net margin | — | -139.81% |
| 52-week high | $22.67 | $50.81 |
| 52-week low | $11.00 | $15.86 |
| Distance from 52-week high | -36.74% | -27.51% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.28% | +62.91% |
| Average volume | 1.05M | 849.01K |
| Shares outstanding | 128.35M | 48.88M |
| Employees | 312 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
GENB vs URGN FAQ
Which is bigger, Generate Biomedicines or UroGen Pharma?
Generate Biomedicines (GENB) is larger, with a market capitalization of $1.84B compared with $1.80B for UroGen Pharma (URGN).
Are Generate Biomedicines and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.